Khella Christen A, Mehta Gaurav A, Mehta Rushabh N, Gatza Michael L
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
J Pers Med. 2021 Feb 19;11(2):149. doi: 10.3390/jpm11020149.
The underlying molecular heterogeneity of cancer is responsible for the dynamic clinical landscape of this disease. The combination of genomic and proteomic alterations, including both inherited and acquired mutations, promotes tumor diversity and accounts for variable disease progression, therapeutic response, and clinical outcome. Recent advances in high-throughput proteogenomic profiling of tumor samples have resulted in the identification of novel oncogenic drivers, tumor suppressors, and signaling networks; biomarkers for the prediction of drug sensitivity and disease progression; and have contributed to the development of novel and more effective treatment strategies. In this review, we will focus on the impact of historical and recent advances in single platform and integrative proteogenomic studies in breast and ovarian cancer, which constitute two of the most lethal forms of cancer for women, and discuss the molecular similarities of these diseases, the impact of these findings on our understanding of tumor biology as well as the clinical applicability of these discoveries.
癌症潜在的分子异质性决定了这种疾病动态变化的临床情况。基因组和蛋白质组改变的组合，包括遗传和获得性突变，促进了肿瘤的多样性，并导致疾病进展、治疗反应和临床结果的差异。肿瘤样本高通量蛋白质基因组分析的最新进展已促成新型致癌驱动因子、肿瘤抑制因子和信号网络的识别；预测药物敏感性和疾病进展的生物标志物；并有助于开发新的、更有效的治疗策略。在本综述中，我们将重点关注单平台和综合蛋白质基因组研究的历史及最新进展对乳腺癌和卵巢癌的影响，这两种癌症是对女性最致命的癌症形式中的两种，并讨论这些疾病的分子相似性、这些发现对我们理解肿瘤生物学的影响以及这些发现的临床适用性。
